MHD患者AVF狭窄的胆汁酸谱代谢组学研究进展
Research Progress on the Bile Acid Metabolome in Arteriovenous Fistula Stenosis among Maintenance Hemodialysis Patients
DOI: 10.12677/acm.2026.1631013, PDF,    科研立项经费支持
作者: 张 佩*, 杨 慧:大理大学临床医学院,云南 大理;杨灵书, 刘丽茹#:大理大学第一附属医院肾脏内科,云南 大理
关键词: 自体动静脉内瘘维持性血液透析胆汁酸代谢组学Arteriovenous Fistula Maintenance Hemodialysis Bile Acid Metabolomics
摘要: 目的:探讨胆汁酸代谢紊乱在维持性血液透析(MHD)患者自体动静脉内瘘(AVF)狭窄中的作用机制及研究进展。方法:广泛查阅并归纳相关文献。结果:AVF狭窄的发生涉及内皮损伤、炎症反应、氧化应激、血管钙化及新生内膜增生等多个病理生理过程。MHD患者因肾功能衰竭及透析治疗,胆汁酸代谢谱发生显著改变,特定的胆汁酸及其信号通路(如FXR、TGR5等)可通过调控全身炎症、血管钙化和直接影响血管内皮细胞功能参与AVF狭窄。结论:胆汁酸代谢紊乱是连接慢性肾脏病全身状态与AVF局部血管病变的重要代谢桥梁,其深入研究为理解AVF狭窄的机制提供了新的研究方向。未来研究需进一步明确关键致病性胆汁酸作用靶点及信号通路,以期发现潜在的生物标志物和治疗新靶点。
Abstract: Objective: To explore the mechanism and research progress of bile acid metabolism disorder in the stenosis of autologous arteriovenous fistula (AVF) in maintenance hemodialysis (MHD) patients. Methods: Conduct extensive research and summarize relevant literature. Results: The occurrence of AVF stenosis involves multiple pathophysiological processes such as endothelial injury, inflammatory response, oxidative stress, vascular calcification, and neointimal hyperplasia. Due to renal failure and dialysis treatment, the bile acid metabolism profile of MHD patients undergoes significant changes. Specific bile acids and their signaling pathways (such as FXR, TGR5, etc.) can participate in AVF stenosis by regulating systemic inflammation, vascular calcification, and directly affecting the function of vascular endothelial cells. Conclusion: Bile acid metabolism disorder is an important metabolic bridge connecting the systemic state of chronic kidney disease and local vascular lesions of AVF. In-depth research provides a new research direction for understanding the mechanism of AVF stenosis. Future studies need to further clarify the key pathogenic bile acid action targets and signaling pathways in order to discover potential biomarkers and new therapeutic targets.
文章引用:张佩, 杨灵书, 杨慧, 刘丽茹. MHD患者AVF狭窄的胆汁酸谱代谢组学研究进展[J]. 临床医学进展, 2026, 16(3): 2204-2210. https://doi.org/10.12677/acm.2026.1631013

参考文献

[1] Wang, L., Xu, X., Zhang, M., Hu, C., Zhang, X., Li, C., et al. (2023) Prevalence of Chronic Kidney Disease in China: Results from the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Internal Medicine, 183, 298-310. [Google Scholar] [CrossRef] [PubMed]
[2] Liyanage, T., Toyama, T., Hockham, C., Ninomiya, T., Perkovic, V., Woodward, M., et al. (2022) Prevalence of Chronic Kidney Disease in Asia: A Systematic Review and Analysis. BMJ Global Health, 7, e007525. [Google Scholar] [CrossRef] [PubMed]
[3] Bikbov, B., Purcell, C.A., Levey, A.S., Smith, M., Abdoli, A., Abebe, M., et al. (2020) Global, Regional, and National Burden of Chronic Kidney Disease, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 395, 709-733. [Google Scholar] [CrossRef] [PubMed]
[4] Du, J., Liang, L., Liu, S., Yang, X., Cao, S., Zhang, H., et al. (2020) Neointimal Hyperplasia in the Inferior Vena Cava of Adenine-Induced Chronic Kidney Disease Rats with Aortocaval Fistulas. Clinical and Experimental Nephrology, 24, 1007-1014. [Google Scholar] [CrossRef] [PubMed]
[5] 于平, 邹春波. 微炎症与维持性血液透析患者主动脉弓钙化的相关性研究[J]. 大连医科大学学报, 2022, 44(3): 218-223.
[6] Lau, W.L., Savoj, J., Nakata, M.B. and Vaziri, N.D. (2018) Altered Microbiome in Chronic Kidney Disease: Systemic Effects of Gut-Derived Uremic Toxins. Clinical Science, 132, 509-522. [Google Scholar] [CrossRef] [PubMed]
[7] Evenepoel, P., Poesen, R. and Meijers, B. (2016) The Gut-Kidney Axis. Pediatric Nephrology, 32, 2005-2014. [Google Scholar] [CrossRef] [PubMed]
[8] Goek, O., Prehn, C., Sekula, P., Römisch-Margl, W., Döring, A., Gieger, C., et al. (2013) Metabolites Associate with Kidney Function Decline and Incident Chronic Kidney Disease in the General Population. Nephrology Dialysis Transplantation, 28, 2131-2138. [Google Scholar] [CrossRef] [PubMed]
[9] Kobayashi, T., Yoshida, T., Fujisawa, T., Matsumura, Y., Ozawa, T., Yanai, H., et al. (2014) A Metabolomics-Based Approach for Predicting Stages of Chronic Kidney Disease. Biochemical and Biophysical Research Communications, 445, 412-416. [Google Scholar] [CrossRef] [PubMed]
[10] Altenbuchinger, M., Zacharias, H.U., Solbrig, S., Schäfer, A., Büyüközkan, M., Schultheiß, U.T., et al. (2019) A Multi-Source Data Integration Approach Reveals Novel Associations between Metabolites and Renal Outcomes in the German Chronic Kidney Disease Study. Scientific Reports, 9, Article No. 13954. [Google Scholar] [CrossRef] [PubMed]
[11] Chu, L., Zhang, K., Zhang, Y., Jin, X. and Jiang, H. (2014) Mechanism Underlying an Elevated Serum Bile Acid Level in Chronic Renal Failure Patients. International Urology and Nephrology, 47, 345-351. [Google Scholar] [CrossRef] [PubMed]
[12] Li, R., Zeng, L., Xie, S., Chen, J., Yu, Y. and Zhong, L. (2019) Targeted Metabolomics Study of Serum Bile Acid Profile in Patients with End-Stage Renal Disease Undergoing Hemodialysis. PeerJ, 7, e7145. [Google Scholar] [CrossRef] [PubMed]
[13] Zhu, K., Li, R., Qiu, Z., Yu, H., Xu, K., Li, R., et al. (2025) Circulating Bile Acids, Bile Acid Receptor Polymorphisms, and Risk of Chronic Kidney Disease among Individuals with Newly Diagnosed Type 2 Diabetes: A Prospective Study. The American Journal of Clinical Nutrition, 122, 841-852. [Google Scholar] [CrossRef] [PubMed]
[14] Ghallab, A., González, D., Strängberg, E., Hofmann, U., Myllys, M., Hassan, R., et al. (2024) Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis. Journal of Hepatology, 80, 268-281. [Google Scholar] [CrossRef] [PubMed]
[15] Chen, W., Zhang, J., Chen, L., Byrne, C.D., Targher, G., Luo, L., et al. (2025) Bioactive Metabolites: A Clue to the Link between MASLD and CKD? Clinical and Molecular Hepatology, 31, 56-73. [Google Scholar] [CrossRef] [PubMed]
[16] 梁心议, 王桃霞, 刘晓丽, 等. 自体动静脉内瘘狭窄机制的研究进展[J]. 中国血液净化, 2024, 23(8): 609-611+640.
[17] Alpers, C.E., Imrey, P.B., Hudkins, K.L., Wietecha, T.A., Radeva, M., Allon, M., et al. (2017) Histopathology of Veins Obtained at Hemodialysis Arteriovenous Fistula Creation Surgery. Journal of the American Society of Nephrology, 28, 3076-3088. [Google Scholar] [CrossRef] [PubMed]
[18] Viecelli, A.K., Mori, T.A., Roy‐Chaudhury, P., Polkinghorne, K.R., Hawley, C.M., Johnson, D.W., et al. (2017) The Pathogenesis of Hemodialysis Vascular Access Failure and Systemic Therapies for Its Prevention: Optimism Unfulfilled. Seminars in Dialysis, 31, 244-257. [Google Scholar] [CrossRef] [PubMed]
[19] Roy‐Chaudhury, P. and Kruska, L. (2015) Future Directions for Vascular Access for Hemodialysis. Seminars in Dialysis, 28, 107-113. [Google Scholar] [CrossRef] [PubMed]
[20] Zhao, Y., Li, Z., Ma, H., Pan, Z., Cai, B., Zhang, C., et al. (2025) METTL3-Mediated m6A MRNA Modification Facilitates Neointimal Hyperplasia in Arteriovenous Fistula. Arteriosclerosis, Thrombosis, and Vascular Biology, 45, 1124-1144. [Google Scholar] [CrossRef] [PubMed]
[21] Hammes, M. (2015) Hemodynamic and Biologic Determinates of Arteriovenous Fistula Outcomes in Renal Failure Patients. BioMed Research International, 2015, Article ID: 171674. [Google Scholar] [CrossRef] [PubMed]
[22] Wasse, H., Huang, R., Naqvi, N., Smith, E., Wang, D. and Husain, A. (2012) Inflammation, Oxidation and Venous Neointimal Hyperplasia Precede Vascular Injury from AVF Creation in CKD Patients. The Journal of Vascular Access, 13, 168-174. [Google Scholar] [CrossRef] [PubMed]
[23] Kilari, S., DeMartino, R.R., Nyberg, S.L., Dean, P.G., Colglazier, J.J., Takahashi, E., et al. (2025) Periadventitial Delivery of Mesenchymal Stem Cells Improves Vascular Remodeling and Maturation in Arteriovenous Fistulas. Science Translational Medicine, 17, eadp7723. [Google Scholar] [CrossRef] [PubMed]
[24] Zhao, M., Wu, Q., Zhao, Y., Nian, R., Li, W. and Lu, H. (2025) Tissue Metabolomics Reveals Metabolic Dysregulation Associated with Intimal Hyperplasia in Arteriovenous Fistula Stenosis. Frontiers in Physiology, 16, Article ID: 1638179. [Google Scholar] [CrossRef
[25] 廖露. 基于代谢组学分析探讨维持性血液透析患者自体动静脉内瘘狭窄的机制研究[D]: [硕士学位论文]. 南昌: 南昌大学, 2023.
[26] Shapiro, H., Kolodziejczyk, A.A., Halstuch, D. and Elinav, E. (2018) Bile Acids in Glucose Metabolism in Health and Disease. Journal of Experimental Medicine, 215, 383-396. [Google Scholar] [CrossRef] [PubMed]
[27] Li, T. and Chiang, J.Y.L. (2024) Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development. Pharmacological Reviews, 76, 1221-1253. [Google Scholar] [CrossRef] [PubMed]
[28] Barbier, O., Torra, I.P., Sirvent, A., Claudel, T., Blanquart, C., Duran-Sandoval, D., et al. (2003) FXR Induces the UGT2B4 Enzyme in Hepatocytes: A Potential Mechanism of Negative Feedback Control of FXR Activity. Gastroenterology, 124, 1926-1940. [Google Scholar] [CrossRef] [PubMed]
[29] Li, T. and Chiang, J.Y.L. (2014) Bile Acid Signaling in Metabolic Disease and Drug Therapy. Pharmacological Reviews, 66, 948-983. [Google Scholar] [CrossRef] [PubMed]
[30] 白一锋, 靳春荣, 贾鸳鸯, 等. 基于胆汁酸代谢探讨动脉粥样硬化的发病机制[J]. 中西医结合心脑血管病杂志, 2024, 22(1): 103-108.
[31] Marchianò, S., Biagioli, M., Bordoni, M., Morretta, E., Di Giorgio, C., Vellecco, V., et al. (2023) Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G‐Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease. Journal of the American Heart Association, 12, e031241. [Google Scholar] [CrossRef] [PubMed]
[32] Miyazaki-Anzai, S., Masuda, M., Levi, M., Keenan, A.L. and Miyazaki, M. (2014) Dual Activation of the Bile Acid Nuclear Receptor FXR and G-Protein-Coupled Receptor TGR5 Protects Mice against Atherosclerosis. PLOS ONE, 9, e108270. [Google Scholar] [CrossRef] [PubMed]
[33] Han, Y., Du, B., Zhu, X., Wang, Y., Zheng, H. and Liu, W. (2024) Lipid Metabolism Disorder in Diabetic Kidney Disease. Frontiers in Endocrinology, 15, Article ID: 1336402. [Google Scholar] [CrossRef] [PubMed]
[34] Dana Grosu, I., Stirbu, O., Gadalean, F., Bob, F., Mihaescu, A., Marc, L., et al. (2022) MO790: Arteriovenous Fistula Calcifications—Risk Factors and Impact on Arteriovenous Fistula Functionality. Nephrology Dialysis Transplantation, 37, gfac080.027. [Google Scholar] [CrossRef
[35] 黄文彤, 隋晓露, 谢婷妃, 等. 动静脉内瘘功能障碍机制的研究进展[J]. 中国医师杂志, 2024, 26(6): 958-960.
[36] Bartlett, M., Bonfanti, M., Diaz-Zuccarini, V. and Tsui, J. (2024) Computationally Enhanced, Haemodynamic Case Study of Neointimal Hyperplasia Development in a Dialysis Access Fistula. Reviews in Cardiovascular Medicine, 25, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[37] Fiorucci, S., Zampella, A., Cirino, G., Bucci, M. and Distrutti, E. (2017) Decoding the Vasoregulatory Activities of Bile Acid-Activated Receptors in Systemic and Portal Circulation: Role of Gaseous Mediators. American Journal of Physiology-Heart and Circulatory Physiology, 312, H21-H32. [Google Scholar] [CrossRef] [PubMed]
[38] Lu, H., Wu, Z., Wan, M., Xiong, S., Huang, X., Liu, T., et al. (2025) Taurochenodeoxycholic Acid Alleviates Obesity-Induced Endothelial Dysfunction. European Heart Journal, ehaf766. [Google Scholar] [CrossRef
[39] Kida, T., Tsubosaka, Y., Hori, M., Ozaki, H. and Murata, T. (2013) Bile Acid Receptor TGR5 Agonism Induces NO Production and Reduces Monocyte Adhesion in Vascular Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 33, 1663-1669. [Google Scholar] [CrossRef] [PubMed]
[40] Kida, T., Omori, K., Hori, M., Ozaki, H. and Murata, T. (2014) Stimulation of G Protein-Coupled Bile Acid Receptor Enhances Vascular Endothelial Barrier Function via Activation of Protein Kinase A and RAC1. The Journal of Pharmacology and Experimental Therapeutics, 348, 125-130. [Google Scholar] [CrossRef] [PubMed]